Literature DB >> 18366999

Why is HDL functionally deficient in type 2 diabetes?

Anatol Kontush1, M John Chapman.   

Abstract

High-density lipoprotein (HDL) particles exert a spectrum of atheroprotective activities that can be deficient in type 2 diabetes. Key mechanisms leading to the formation of functionally deficient HDL involve 1) HDL enrichment in triglycerides and depletion in cholesteryl esters with conformational alterations of apolipoprotein A-I; 2) glycation of apolipoproteins and/or HDL-associated enzymes; and 3) oxidative modification of HDL lipids, apolipoproteins, and/or enzymes. Available data identify hypertriglyceridemia, with concomitant compositional modification of the HDL lipid core and conformational change of apolipoprotein A-I, as a driving force in functional alteration of HDL particles in type 2 diabetes. Therapeutic options for correcting HDL functional deficiency should target hypertriglyceridemia by normalizing circulating levels of triglyceride-rich lipoproteins.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18366999     DOI: 10.1007/s11892-008-0010-5

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  59 in total

Review 1.  The role of high-density lipoproteins in oxidation and inflammation.

Authors:  B J Van Lenten; M Navab; D Shih; A M Fogelman; A J Lusis
Journal:  Trends Cardiovasc Med       Date:  2001 Apr-May       Impact factor: 6.677

2.  The failure of torcetrapib: was it the molecule or the mechanism?

Authors:  Alan R Tall; Laurent Yvan-Charvet; Nan Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-02       Impact factor: 8.311

3.  Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes.

Authors:  Maria Mastorikou; Mike Mackness; Bharti Mackness
Journal:  Diabetes       Date:  2006-11       Impact factor: 9.461

4.  Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.

Authors:  K Julier; M I Mackness; J D Dean; P N Durrington
Journal:  Diabet Med       Date:  1999-05       Impact factor: 4.359

5.  Inability of HDL from abdominally obese subjects to counteract the inhibitory effect of oxidized LDL on vasorelaxation.

Authors:  Laurence Perségol; Bruno Vergès; Philippe Gambert; Laurence Duvillard
Journal:  J Lipid Res       Date:  2007-02-28       Impact factor: 5.922

6.  HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.

Authors:  S M Sanguinetti; F D Brites; V Fasulo; J Verona; A Elbert; R L Wikinski; L E Schreier
Journal:  Diabetes Nutr Metab       Date:  2001-02

7.  Effects of the neutral lipid content of high density lipoprotein on apolipoprotein A-I structure and particle stability.

Authors:  D L Sparks; W S Davidson; S Lund-Katz; M C Phillips
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

8.  Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity.

Authors:  Boris Hansel; Philippe Giral; Estelle Nobecourt; Sandrine Chantepie; Eric Bruckert; M John Chapman; Anatol Kontush
Journal:  J Clin Endocrinol Metab       Date:  2004-10       Impact factor: 5.958

9.  The relationship of chemical modification of membrane proteins and plasma lipoproteins to reduced membrane fluidity of erythrocytes from diabetic subjects.

Authors:  C Watala; P D Winocour
Journal:  Eur J Clin Chem Clin Biochem       Date:  1992-09

10.  Characterization of the non enzymatic glycation of high density lipoprotein in diabetic patients.

Authors:  C Calvo; G Ponsin; F Berthezene
Journal:  Diabete Metab       Date:  1988 May-Jun
View more
  25 in total

1.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

2.  Oxidized high density lipoprotein induces macrophage apoptosis via toll-like receptor 4-dependent CHOP pathway.

Authors:  Shutong Yao; Hua Tian; Li Zhao; Jinguo Li; Libo Yang; Feng Yue; Yanyan Li; Peng Jiao; Nana Yang; Yiwei Wang; Xiangjian Zhang; Shucun Qin
Journal:  J Lipid Res       Date:  2016-11-28       Impact factor: 5.922

3.  Nonenzymatic glycation impairs the antiinflammatory properties of apolipoprotein A-I.

Authors:  Estelle Nobécourt; Fatiha Tabet; Gilles Lambert; Rajesh Puranik; Shisan Bao; Ling Yan; Michael J Davies; Bronwyn E Brown; Alicia J Jenkins; Gregory J Dusting; David J Bonnet; Linda K Curtiss; Philip J Barter; Kerry-Anne Rye
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-01-28       Impact factor: 8.311

4.  Plasma lipids, lipoprotein metabolism and HDL lipid transfers are equally altered in metabolic syndrome and in type 2 diabetes.

Authors:  Vanessa M Silva; Carmen G C Vinagre; Luis A O Dallan; Ana P M Chacra; Raul C Maranhão
Journal:  Lipids       Date:  2014-04-10       Impact factor: 1.880

5.  The Application of Multiple Reaction Monitoring to Assess Apo A-I Methionine Oxidations in Diabetes and Cardiovascular Disease.

Authors:  Hussein N Yassine; Angela M Jackson; Peter D Reaven; Dobrin Nedelkov; Randall W Nelson; Serrine S Lau; Christoph H Borchers
Journal:  Transl Proteom       Date:  2014-12-01

Review 6.  Dysfunctional HDL and atherosclerotic cardiovascular disease.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin J Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Nat Rev Cardiol       Date:  2015-09-01       Impact factor: 32.419

Review 7.  Dysfunctional HDL as a diagnostic and therapeutic target.

Authors:  Jonathan D Smith
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-13       Impact factor: 8.311

Review 8.  Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes.

Authors:  Hussein Yassine; Chad R Borges; Matthew R Schaab; Dean Billheimer; Craig Stump; Peter Reaven; Serrine S Lau; Randall Nelson
Journal:  Proteomics Clin Appl       Date:  2013-07-09       Impact factor: 3.494

9.  Elevated serum uric acid in nondiabetic people mark pro-inflammatory state and HDL dysfunction and independently predicts coronary disease.

Authors:  Altan Onat; Günay Can; Ender Örnek; Servet Altay; Murat Yüksel; Evin Ademoğlu
Journal:  Clin Rheumatol       Date:  2013-08-11       Impact factor: 2.980

10.  Lipid measures for prediction of incident cardiovascular disease in diabetic and non-diabetic adults: results of the 8.6 years follow-up of a population based cohort study.

Authors:  Maryam Tohidi; Masumeh Hatami; Farzad Hadaegh; Maryam Safarkhani; Hadi Harati; Fereidoun Azizi
Journal:  Lipids Health Dis       Date:  2010-01-23       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.